Head-to-head · WeighScore
Found vs NuuVim
The verdict
Found takes it — 83.5/100 to 68.2/100.
Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The broadest medication bench on the board — compounded, brand-name and oral orforglipron — priced off a membership rather than a sticker.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Found | NuuVim |
|---|---|---|
| WeighScore | 83.5/100 | 68.2/100 |
| Grade | B | C |
| Scorecard rank | #14 | #153 |
| Semaglutide | Compounded from $99/mo | $79/mo (all doses, 3-mo plan, new patients only, compounded) |
| Tirzepatide | Compounded from $99/mo | $133/mo (all doses, 3-mo plan, new patients only, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Graded #14 · B
Strengths
- Widest medication list on this board — compounded semaglutide and tirzepatide, brand Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Victoza, plus oral Foundayo (orforglipron) and Rybelsus
- Flat pricing as the dose increases, so a titration does not raise the monthly cost
- Bills insurance for the clinical visits — the site states most members pay under $30 per visit
- Runs a dedicated GLP-1 microdose programme for people who want a lower starting dose
Where it loses points
- The $99/mo headline is a longer-plan floor — Found's own FAQ says 3, 6 and 12-month plans are what keep the monthly cost down, so month-to-month costs meaningfully more
- Medication cost is separate from the membership and clinical care, so no advertised figure is the all-in number
- The homepage insurance selector lists roughly 41 states, not 50 — coverage is narrower than the service footprint
- Compounded medication is not FDA-approved the way brand Wegovy or Zepbound are
Graded #153 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- There is no month-to-month plan: every rate is billed as one three-month payment
- The advertised $79 and $133 are introductory rates for customers new to GLP-1s; on renewal they become $133 and $199.67
- The site's own llms.txt advertises pricing, FAQ and terms files that all 404
- No state count is published
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.